Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Convertible Debt (2022 - 2025)

Gossamer Bio's Convertible Debt history spans 4 years, with the latest figure at $198.5 million for Q4 2025.

  • For Q4 2025, Convertible Debt changed 0.5% year-over-year to $198.5 million; the TTM value through Dec 2025 reached $198.5 million, changed 0.5%, while the annual FY2025 figure was $198.5 million, 0.5% changed from the prior year.
  • Convertible Debt reached $198.5 million in Q4 2025 per GOSS's latest filing, roughly flat from $198.3 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $198.5 million in Q4 2025 to a low of $195.1 million in Q1 2022.
  • Average Convertible Debt over 4 years is $196.7 million, with a median of $196.7 million recorded in 2023.
  • Peak YoY movement for Convertible Debt: increased 0.43% in 2023, then increased 0.5% in 2025.
  • A 4-year view of Convertible Debt shows it stood at $195.7 million in 2022, then grew by 0.45% to $196.6 million in 2023, then grew by 0.47% to $197.5 million in 2024, then rose by 0.5% to $198.5 million in 2025.
  • Per Business Quant, the three most recent readings for GOSS's Convertible Debt are $198.5 million (Q4 2025), $198.3 million (Q3 2025), and $198.0 million (Q2 2025).